Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.17
-0.03 (-0.16%)
At close: May 27, 2026, 4:00 PM EDT
19.07
-0.10 (-0.52%)
Pre-market: May 28, 2026, 4:55 AM EDT
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Monte Rosa Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $32.33. The average 1-year stock price forecast is 68.65% higher than the current stock price, while the lowest is $29 (+51.28%) and the highest is $37 (+93.01%).
Price Target: $32.33 (+68.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $30 → $31 | Buy | Reiterates | $30 → $31 | +61.71% | May 11, 2026 |
| Wedbush | Wedbush | Buy Maintains $37 | Buy | Maintains | $37 | +93.01% | May 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $37 | Buy | Reiterates | $37 | +93.01% | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 7, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Financial Forecast
Revenue This Year
20.46M
from 123.67M
Decreased by -83.46%
Revenue Next Year
20.60M
from 20.46M
Increased by 0.71%
EPS This Year
-2.00
from -0.46
EPS Next Year
-2.22
from -2.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 49.9M | 42.0M | ||||||
| Avg | 20.5M | 20.6M | ||||||
| Low | 3.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -59.6% | 105.3% | ||||||
| Avg | -83.5% | 0.7% | ||||||
| Low | -96.8% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -1.86 | -1.81 | ||||
| Avg | -2.00 | -2.22 | ||||
| Low | -2.20 | -2.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.